Date: 2012-11-29
Type of information:
phase:
Announcement: presentation of resultsat the 8th Annual European Antibody Congress in Geneva, Switzerland
Company: Pieris (Germany)
Product: PRS-190 bispecific Anticalin program
Action mechanism: Anticalins are novel, next generation therapeutic proteins designed to bind and antagonize a wide spectrum of ligands. These monomeric therapeutic proteins are derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. The multispecific approach, including Duocalins, takes advantage of Anticalins’ free N- and C-terminal ends, whereby individual Anticalins can be pieced together as fusion proteins without interfering with the ligand-binding regions.
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: In a presentation at the 8th Annual European Antibody Congress in Geneva, Pieris AG presented for the first time data for its PRS-190 bispecific Anticalin program targeting the Th17 pathway. The data revealed the generation of a highly specific and potent bispecific antagonist targeting IL-17 and IL-23, two key members of the Th17 family of cytokines, involved in autoimmunity and hyperinflammation. The single-gene multispecific drug candidate, whose individual building blocks could surpass existing available therapies against their respective target, creates several benefits ranging from efficacy, convenience, accelerated development timelines, ease of manufacturing and cost. In a presentation entitled “Anticalins: Clinical Stage Next Generation Therapeutics with Superior Differentiating Features”, data from the PRS-190 program demonstrated the functionality of the separate Anticalin building blocks, as well as the combined Duocalin compound.
“The PRS-190 bispecific Anticalin, or Duocalin®, is a first-in-class drug candidate that we expect to have relevance in a broad range of diseases not effectively treated today,” said Stephen Yoder, CEO of Pieris. “The most advanced Duocalin in development at Pieris, PRS-190 has cleared the path for more multispecific approaches—not just bispecifics—an area to which we are fully committed.”
